Access For Life

Company Overview

Snapshot

Founded in September 2013 by Roger Mason, Access For Life operates with 1-10 employees. The company has secured funding across two rounds from Pharmes Innovations Limited, and received a grant from EU Horizon 2020.

Business overview

Access For Life develops medical devices aimed at facilitating repetitive therapies requiring vascular access for patients with chronic diseases. Its core product, the patented JEM device, is a smart needle guide designed to preserve vessel walls and reduce complications during vascular access, particularly for hemodialysis and potentially chemotherapy. The device, which attaches directly to an arterio-venous (AV) fistula or graft and is implanted subcutaneously, aims to enable easier and safer needle insertion, reduce pain with blunt needles, and support home and self-care hemodialysis. Additionally, the JEM device incorporates sensors for ultrasound and velocity measurements, providing clinical data for healthcare providers and enabling big data analysis related to dialysis. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers and patients in markets such as Canada and Taiwan.

Company Intelligence Q&A

What is Access For Life's primary product?

Access For Life's primary product is the JEM device, a patented subcutaneous implanted device designed as a smart needle guide for vascular access in patients requiring repetitive therapies like hemodialysis.

When was Access For Life founded?

Access For Life was founded in September 2013.

Who is a key founder of Access For Life?

Roger Mason is a founder and CMO of Access For Life.

Which investor participated in Access For Life's funding round in January 2016?

In January 2016, Pharmes Innovations Limited participated in a funding round for Access For Life.